NCT00132808

Zoledronic Acid in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia, 45 Years of Age and Older

A 2-year Randomized, Multicenter, Double-blind, Placebo-controlled Study to Determine the Efficacy and Safety of Intravenous Zoledronic Acid 5 mg Administered Either Annually at Randomization and 12 Months, or Administered at Randomization Only in the Prevention of Bone Loss in Postmenopausal Women With Osteopenia

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 581 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: Female
• Age: 45 Years
• Healthy volunteers: Not accepted

Summary

Osteoporosis prevention is important in patients with osteopenia (low bone density). This study will test the safety and efficacy of zoledronic acid in patients diagnosed with osteopenia.

Conditions

• Osteopenia

Interventions

Type	Name	Description
DRUG	Zoledronic Acid	Zoledronic acid 5 mg intravenous
DRUG	Placebo	Physiologic 0.9% normal saline

Timeline

• Start date: 2004-07-01
• Primary completion: 2008-02-01
• Completion: 2008-02-01
• First posted: 2005-08-22
• Last updated: 2016-09-12
• Results posted: 2011-01-10

Locations

1 site across 1 country: United States